TAp73 promotes anti-senescence-anabolism not proliferation

Aging

Volumn 6, Issue 11, 2014, Pages 921-930

  Agostini, Massimiliano ^a,b   Niklison Chirou, Maria Victoria ^a,d   Catani, Maria Valeria ^b   Knight, Richard A ^a   Melino, Gerry ^a,b   Rufini, Alessandro ^a,c  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aging; Apotosis; Cancer; Metabolism; P53 family; p73; Senescence

Indexed keywords

DNA BINDING PROTEIN; NUCLEAR PROTEIN; NUCLEOTIDE; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ANIMAL; BIOSYNTHESIS; BONE TUMOR; BRAIN CORTEX; C57BL MOUSE; CELL AGING; CELL CYCLE CHECKPOINT; CELL DEATH; CELL PROLIFERATION; DEFICIENCY; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HIPPOCAMPUS; HUMAN; KNOCKOUT MOUSE; METABOLISM; OSTEOSARCOMA; PATHOLOGY; PENTOSE PHOSPHATE CYCLE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; CELL AGING; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CEREBRAL CORTEX; DNA-BINDING PROTEINS; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HIPPOCAMPUS; HUMANS; MICE, INBRED C57BL; MICE, KNOCKOUT; NUCLEAR PROTEINS; NUCLEOTIDES; OSTEOSARCOMA; PENTOSE PHOSPHATE PATHWAY; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84920271599     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100701     Document Type: Article

References (95)

1. Schulze A and Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012; 491:364-373.
2. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
3. Markert EK, Levine AJ and Vazquez A. Proliferation and tissue remodeling in cancer: the hallmarks revisited. Cell death & disease. 2012; 3:e397.
4. Zhao Y, Butler EB and Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell death & disease. 2013; 4:e532.
5. Sotgia F, Martinez-Outschoorn UE and Lisanti MP. Cancer metabolism: new validated targets for drug discovery. Oncotarget. 2013; 4:1309-1316.
6. Garufi A, Ricci A, Trisciuoglio D, Iorio E, Carpinelli G, Pistritto G, Cirone M and D'Orazi G. Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy. Cell death & disease. 2013; 4:e639.
7. Selvarajah J, Nathawat K, Moumen A, Ashcroft M and Carroll VA. Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways. Cell death & disease. 2013; 4:e865.
8. Hill R, Rabb M, Madureira PA, Clements D, Gujar SA, Waisman DM, Giacomantonio CA and Lee PW. Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Cell death & disease. 2013; 4:e791.
9. Favaro E and Harris AL. Targeting glycogen metabolism: a novel strategy to inhibit cancer cell growth? Oncotarget. 2013; 4:3-4.
10. Cairns RA, Harris IS and Mak TW. Regulation of cancer cell metabolism. Nature reviews Cancer. 2011; 11:85-95.
11. Cook CC, Kim A, Terao S, Gotoh A and Higuchi M. Consumption of oxygen: a mitochondrial-generated progression signal of advanced cancer. Cell death & disease. 2012; 3:e258.
12. Gorrini C, Harris IS and Mak TW. Modulation of oxidative stress as an anticancer strategy. Nature reviews Drug discovery. 2013; 12:931-947.
13. Munoz-Pinedo C, El Mjiyad N and Ricci JE. Cancer metabolism: current perspectives and future directions. Cell death & disease. 2012; 3:e248.
14. Kroemer G and Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer cell. 2008; 13:472-482.
15. Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, Richer JK, Anderson SM and Thor AD. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell cycle. 2013; 12:3759-3769.
16. Yang W and Lu Z. Nuclear PKM2 regulates the Warburg effect. Cell cycle. 2013; 12:3154-3158.
17. Menendez JA and Joven J. One-carbon metabolism: an agingcancer crossroad for the gerosuppressant metformin. Aging (Albany NY). 2012; 4:894-898.
18. De Laurenzi V, Melino G, Savini I, Annicchiarico-Petruzzelli M, Finazzi-Agro A and Avigliano L. Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell lines. European journal of cancer. 1995; 31A:463-466.
19. Levine AJ and Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010; 330:1340-1344.
20. Kang MY, Kim HB, Piao C, Lee KH, Hyun JW, Chang IY and You HJ. The critical role of catalase in prooxidant and antioxidant function of p53. Cell death and differentiation. 2013; 20:117-129.
21. Sanchez-Macedo N, Feng J, Faubert B, Chang N, Elia A, Rushing EJ, Tsuchihara K, Bungard D, Berger SL, Jones RG, Mak TW and Zaugg K. Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type I tumor model. Cell death and differentiation. 2013; 20:659-668.
22. Chen JQ and Russo J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochimica et biophysica acta. 2012; 1826:370-384.
23. Evangelou K, Bartkova J, Kotsinas A, Pateras IS, Liontos M, Velimezi G, Kosar M, Liloglou T, Trougakos IP, Dyrskjot L, Andersen CL, Papaioannou M, Drosos Y, et al. The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell death and differentiation. 2013; 20:1485-1497.
24. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, Iovanna JL, Squire J, Jurisica I, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes & development. 2008; 22:2677-2691.
25. Rosenbluth JM and Pietenpol JA. The jury is in: p73 is a tumor suppressor after all. Genes & development. 2008; 22:2591-2595.
26. Candi E, Agostini M, Melino G and Bernassola F. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Human mutation. 2014; 35:702-714.
27. Conforti F, Sayan AE, Sreekumar R and Sayan BS. Regulation of p73 activity by post-translational modifications. Cell death & disease. 2012; 3:e285.
28. Allocati N, Di Ilio C and De Laurenzi V. p63/p73 in the control of cell cycle and cell death. Experimental cell research. 2012; 318:1285-1290.
29. Tomasini R, Tsuchihara K, Tsuda C, Lau SK, Wilhelm M, Ruffini A, Tsao MS, Iovanna JL, Jurisicova A, Melino G and Mak TW. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:797-802.
30. Liu T, Roh SE, Woo JA, Ryu H and Kang DE. Cooperative role of RanBP9 and P73 in mitochondria-mediated apoptosis. Cell death & disease. 2013; 4:e476.
31. Rufini A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A, Federici M, Dinsdale D, Knight RA, Melino G and Mak TW. TAp73 depletion accelerates aging through metabolic dysregulation. Genes & development. 2012; 26:2009-2014.
32. Amelio I, Markert EK, Rufini A, Antonov AV, Sayan BS, Tucci P, Agostini M, Mineo TC, Levine AJ and Melino G. p73 regulates serine biosynthesis in cancer. Oncogene. 2013.
33. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011; 476:346-350.
34. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature genetics. 2011; 43:869-874.
35. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, Mak TW, Wu M and Yang X. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nature cell biology. 2013; 15:991-1000.
36. Jiang P, Du W and Yang X. A critical role of glucose-6-phosphate dehydrogenase in TAp73-mediated cell proliferation. Cell cycle. 2013; 12:3720-3726.
37. Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, Chan LL, Qiu J, DiPaola RS, Hirshfield KM, Boros LG, Bertino JR, Oltvai ZN, et al. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell death & disease. 2013; 4:e877.
38. Killick R, Niklison-Chirou M, Tomasini R, Bano D, Rufini A, Grespi F, Velletri T, Tucci P, Sayan BS, Conforti F, Gallagher E, Nicotera P, Mak TW, et al. p73: a multifunctional protein in neurobiology. Molecular neurobiology. 2011; 43:139-146.
39. Inoue S, Tomasini R, Rufini A, Elia AJ, Agostini M, Amelio I, Cescon D, Dinsdale D, Zhou L, Harris IS, Lac S, Silvester J, Li WY, et al. TAp73 is required for spermatogenesis and the maintenance of male fertility. Proc Natl Acad Sci U S A. 2014; 111:1843-1848.
40. Levine AJ, Tomasini R, McKeon FD, Mak TW and Melino G. The p53 family: guardians of maternal reproduction. Nature reviews Molecular cell biology. 2011; 12:259-265.
41. Grespi F and Melino G. P73 and age-related diseases: is there any link with Parkinson Disease? Aging. 2012; 4:923-931.
42. Flores ER and Lozano G. The p53 family grows old. Genes & development. 2012; 26:1997-2000.
43. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, Knight RA, Green DR, Thompson C and Vousden KH. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. The Journal of biological chemistry. 2004; 279:8076-8083.
44. Tucci P, Porta G, Agostini M, Dinsdale D, Iavicoli I, Cain K, Finazzi-Agro A, Melino G and Willis A. Metabolic effects of TiO2 nanoparticles, a common component of sunscreens and cosmetics, on human keratinocytes. Cell death & disease. 2013; 4:e549.
45. He Z, Liu H, Agostini M, Yousefi S, Perren A, Tschan MP, Mak TW, Melino G and Simon HU. p73 regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene. Cell death and differentiation. 2013; 20:1415-1424.
46. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, Mueller M, Krammer PH, Melino G and Candi E. p73 induces apoptosis by different mechanisms. Biochemical and biophysical research communications. 2005; 331:713-717.
47. Agostini M, Tucci P, Chen H, Knight RA, Bano D, Nicotera P, McKeon F and Melino G. p73 regulates maintenance of neural stem cell. Biochemical and biophysical research communications. 2010; 403:13-17.
48. Agostini M, Tucci P, Killick R, Candi E, Sayan BS, Rivetti di Val Cervo P, Nicotera P, McKeon F, Knight RA, Mak TW and Melino G. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:21093-21098.
49. Niklison-Chirou MV, Steinert JR, Agostini M, Knight RA, Dinsdale D, Cattaneo A, Mak TW and Melino G. TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75 neurotrophin receptor. Proc Natl Acad Sci U S A. 2013; 110:18952-18957.
50. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R and Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012; 149:1269-1283.
51. Noto A, Raffa S, De Vitis C, Roscilli G, Malpicci D, Coluccia P, Di Napoli A, Ricci A, Giovagnoli MR, Aurisicchio L, Torrisi MR, Ciliberto G and Mancini R. Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells. Cell death & disease. 2013; 4:e947.
52. Liu SY and Zheng PS. High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer. Oncotarget. 2013; 4:2462-2475.
53. Patra KC and Hay N. Hexokinase 2 as oncotarget. Oncotarget. 2013; 4:1862-1863.
54. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer cell. 2013; 24:213-228.
55. Vivanco I. Targeting molecular addictions in cancer. British journal of cancer. 2014. doi: 10.1038/bjc.2014.461.
56. Montero J, Dutta C, van Bodegom D, Weinstock D and Letai A. p53 regulates a non-apoptotic death induced by ROS. Cell death and differentiation. 2013; 20:1465-1474.
57. Sorrentino G, Mioni M, Giorgi C, Ruggeri N, Pinton P, Moll U, Mantovani F and Del Sal G. The prolyl-isomerase Pin1 activates the mitochondrial death program of p53. Cell death and differentiation. 2013; 20:198-208.
58. Valentino T, Palmieri D, Vitiello M, Pierantoni GM, Fusco A and Fedele M. PATZ1 interacts with p53 and regulates expression of p53-target genes enhancing apoptosis or cell survival based on the cellular context. Cell death & disease. 2013; 4:e963.
59. Hutt K, Kerr JB, Scott CL, Findlay JK and Strasser A. How to best preserve oocytes in female cancer patients exposed to DNA damage inducing therapeutics. Cell death and differentiation. 2013; 20:967-968.
60. Kim SY, Cordeiro MH, Serna VA, Ebbert K, Butler LM, Sinha S, Mills AA, Woodruff TK and Kurita T. Rescue of platinumdamaged oocytes from programmed cell death through inactivation of the p53 family signaling network. Cell death and differentiation. 2013; 20:987-997.
61. Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, Ma IT, Rojas Y, Zhao Y, Yu Y, Zhang H, Shohet JM, Nuchtern JG, et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell death & disease. 2013; 4:e867.
62. Ali A, Bluteau O, Messaoudi K, Palazzo A, Boukour S, Lordier L, Lecluse Y, Rameau P, Kraus-Berthier L, Jacquet-Bescond A, Lelievre H, Depil S, Dessen P, et al. Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and-independent mechanisms. Cell death & disease. 2013; 4:e738.
63. Candi E, Rufini A, Terrinoni A, Giamboi-Miraglia A, Lena AM, Mantovani R, Knight R and Melino G. DeltaNp63 regulates thymic development through enhanced expression of FgfR2 and Jag2. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:11999-12004.
64. Sayan BS, Sayan AE, Knight RA, Melino G and Cohen GM. p53 is cleaved by caspases generating fragments localizing to mitochondria. The Journal of biological chemistry. 2006; 281:13566-13573.
65. Fausti F, Di Agostino S, Cioce M, Bielli P, Sette C, Pandolfi PP, Oren M, Sudol M, Strano S and Blandino G. ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence. Cell death and differentiation. 2013; 20:1498-1509.
66. Iannetti A, Ledoux AC, Tudhope SJ, Sellier H, Zhao B, Mowla S, Moore A, Hummerich H, Gewurz BE, Cockell SJ, Jat PS, Willmore E and Perkins ND. Regulation of p53 and Rb Links the Alternative NF-kappaB Pathway to EZH2 Expression and Cell Senescence. PLoS genetics. 2014; 10:e1004642.
67. Qian Y and Chen X. Senescence regulation by the p53 protein family. Methods in molecular biology. 2013; 965:37-61.
68. Paris M, Rouleau M, Puceat M and Aberdam D. Regulation of skin aging and heart development by TAp63. Cell death and differentiation. 2012; 19:186-193.
69. Burnley P, Rahman M, Wang H, Zhang Z, Sun X, Zhuge Q and Su DM. Role of the p63-FoxN1 regulatory axis in thymic epithelial cell homeostasis during aging. Cell death & disease. 2013; 4:e932.
70. Richardson RB. p53 mutations associated with aging-related rise in cancer incidence rates. Cell cycle. 2013; 12:2468-2478.
71. Lin SC and Taatjes DJ. DeltaNp53 and aging. Aging (Albany NY). 2013; 5:717-718.
72. Migliaccio E, Giorgio M and Pelicci PG. p53 and aging: role of p66Shc. Aging. 2013; 5:488-489.
73. McCubrey JA and Demidenko ZN. Recent discoveries in the cycling, growing and aging of the p53 field. Aging (Albany NY). 2012; 4:887-893.
74. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, Karnezis AN and Attardi LD. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 2011; 145:571-583.
75. Hanel W, Marchenko N, Xu S, Yu SX, Weng W and Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell death and differentiation. 2013; 20:898-909.
76. Jiang D, Brady CA, Johnson TM, Lee EY, Park EJ, Scott MP and Attardi LD. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:17123-17128.
77. Mello SS and Attardi LD. Not all p53 gain-of-function mutants are created equal. Cell death and differentiation. 2013; 20:855-857.
78. Haupt S, Gamell C, Wolyniec K and Haupt Y. Interplay between p53 and VEGF: how to prevent the guardian from becoming a villain. Cell death and differentiation. 2013; 20:852-854.
79. Grabow S, Waring P, Happo L, Cook M, Mason KD, Kelly PN and Strasser A. Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice. Cell death and differentiation. 2012; 19:623-632.
80. Blagosklonny MV. Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? Aging. 2012; 4:450-455.
81. Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ, Arner ES and Wiman KG. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell death & disease. 2013; 4:e881.
82. Guerrieri F, Piconese S, Lacoste C, Schinzari V, Testoni B, Valogne Y, Gerbal-Chaloin S, Samuel D, Brechot C, Faivre J and Levrero M. The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells. Cell death & disease. 2013; 4:e807.
83. Bergeaud M, Mathieu L, Guillaume A, Moll UM, Mignotte B, Le Floch N, Vayssiere JL and Rincheval V. Mitochondrial p53 mediates a transcription-independent regulation of cell respiration and interacts with the mitochondrial F(1)F0-ATP synthase. Cell cycle. 2013; 12:2781-2793.
84. Tomasini R, Mak TW and Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends in cell biology. 2008; 18:244-252.
85. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV, Conforti F, Velletri T, Mastino A, Mak TW, Melino G and Knight RA. p73 in Cancer. Genes & cancer. 2011; 2:491-502.
86. Wiman KG. p53 talks to PARP: the increasing complexity of p53-induced cell death. Cell death and differentiation. 2013; 20:1438-1439.
87. Carvajal LA and Manfredi JJ. Another fork in the road-life or death decisions by the tumour suppressor p53. EMBO reports. 2013; 14:414-421.
88. Kracikova M, Akiri G, George A, Sachidanandam R and Aaronson SA. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell death and differentiation. 2013; 20:576-588.
89. Neise D, Sohn D, Stefanski A, Goto H, Inagaki M, Wesselborg S, Budach W, Stuhler K and Janicke RU. The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiationinduced apoptosis and mediates senescence via RSK-and p53-independent accumulation of p21WAF1/CIP1. Cell death & disease. 2013; 4:e859.
90. Chillemi G, Davidovich P, D'Abramo M, Mametnabiev T, Garabadzhiu AV, Desideri A and Melino G. Molecular dynamics of the full-length p53 monomer. Cell cycle. 2013; 12:3098-3108.
91. Marouco D, Garabadgiu AV, Melino G and Barlev NA. Lysinespecific modifications of p53: a matter of life and death? Oncotarget. 2013; 4:1556-1571.
92. Melino G, De Laurenzi V and Vousden KH. p73: Friend or foe in tumorigenesis. Nature reviews Cancer. 2002; 2:605-615.
93. Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M and Zhang R. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell reports. 2013; 3:1252-1265.
94. Darzynkiewicz Z. Perturbation of nucleotide metabolism-the driving force of oncogene-induced senescence. Oncotarget. 2013; 4:649-650.
95. Billon N, Terrinoni A, Jolicoeur C, McCarthy A, Richardson WD, Melino G and Raff M. Roles for p53 and p73 during oligodendrocyte development. Development. 2004; 131:1211-1220.